SG10201708547YA - Compositions and methods for treating and preventing macular degeneration - Google Patents

Compositions and methods for treating and preventing macular degeneration

Info

Publication number
SG10201708547YA
SG10201708547YA SG10201708547YA SG10201708547YA SG10201708547YA SG 10201708547Y A SG10201708547Y A SG 10201708547YA SG 10201708547Y A SG10201708547Y A SG 10201708547YA SG 10201708547Y A SG10201708547Y A SG 10201708547YA SG 10201708547Y A SG10201708547Y A SG 10201708547YA
Authority
SG
Singapore
Prior art keywords
compositions
treating
methods
macular degeneration
preventing macular
Prior art date
Application number
SG10201708547YA
Inventor
Samuel Wadsworth
Abraham Scaria
Chi-Chao Chan
Original Assignee
Genzyme Corp
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Us Health filed Critical Genzyme Corp
Publication of SG10201708547YA publication Critical patent/SG10201708547YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
SG10201708547YA 2013-04-17 2014-04-17 Compositions and methods for treating and preventing macular degeneration SG10201708547YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361813014P 2013-04-17 2013-04-17

Publications (1)

Publication Number Publication Date
SG10201708547YA true SG10201708547YA (en) 2017-11-29

Family

ID=50942311

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201508297YA SG11201508297YA (en) 2013-04-17 2014-04-17 Compositions and methods for treating and preventing macular degeneration
SG10201708547YA SG10201708547YA (en) 2013-04-17 2014-04-17 Compositions and methods for treating and preventing macular degeneration
SG10201912901YA SG10201912901YA (en) 2013-04-17 2014-04-17 Compositions and methods for treating and preventing macular degeneration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201508297YA SG11201508297YA (en) 2013-04-17 2014-04-17 Compositions and methods for treating and preventing macular degeneration

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912901YA SG10201912901YA (en) 2013-04-17 2014-04-17 Compositions and methods for treating and preventing macular degeneration

Country Status (8)

Country Link
US (2) US10640771B2 (en)
EP (2) EP3741385A1 (en)
CN (2) CN105682674A (en)
AU (1) AU2014253919B2 (en)
CA (2) CA3182572A1 (en)
MX (1) MX2015014568A (en)
SG (3) SG11201508297YA (en)
WO (1) WO2014172560A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012094300A2 (en) * 2011-01-04 2012-07-12 The United States of America, as represented by the Secretary, Department of Health and Human Services Office of Technology Transfer National Institutes of Health Methods of treating age-related macular degeneration
AU2015213770A1 (en) * 2014-02-06 2016-09-01 Genzyme Corporation Compositions and methods for treating and preventing macular degeneration
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
WO2018035441A1 (en) * 2016-08-19 2018-02-22 Colorado State University Research Foundation Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virus
CA3073137A1 (en) 2016-08-19 2018-02-22 Jeffrey S. Bartlett Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
MX2019006614A (en) 2016-12-07 2019-10-15 Univ Florida IL-1RA CDNAs.
EP4010361A4 (en) * 2019-08-06 2023-08-09 Children's Medical Center Corporation Methods and compositions for reconstituting microglia
WO2023089151A1 (en) * 2021-11-19 2023-05-25 The University Of Bristol Materials and methods for treatment of macular degeneration

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE10399032I1 (en) 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
FR2658432B1 (en) 1990-02-22 1994-07-01 Medgenix Group Sa MICROSPHERES FOR THE CONTROLLED RELEASE OF WATER-SOLUBLE SUBSTANCES AND PREPARATION METHOD.
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ES2197145T3 (en) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services TRANSFER OF GENES MEDIATED BY ADENOVIRUS TO GASTROINTESTINAL.
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
SI1445322T2 (en) 1995-06-15 2012-10-30 Crucell Holland Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
WO2001002440A1 (en) 1999-07-02 2001-01-11 Genentech, Inc. Fusion peptides comprising a peptide ligand domain and a multimerization domain
EP1204739B1 (en) 1999-08-09 2008-08-06 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
AU2001257611A1 (en) 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
DE60117550T2 (en) 2000-06-01 2006-12-07 University Of North Carolina At Chapel Hill DOUBLE-SIDED PARVOVIRUS VECTORS
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
PT1625210E (en) 2003-05-21 2011-03-15 Genzyme Corp Methods for producing preparations of recombinant aav virions substantially free of empty capsids
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
CA2632435A1 (en) * 2005-12-22 2007-06-28 Laboratoires Serono S.A. Soluble il-17rc variant and uses thereof
EP2666783B1 (en) * 2007-09-25 2019-06-26 Genzyme Corporation Compositions for inhibiting interleukin-23 pathways
PE20121094A1 (en) * 2009-03-05 2012-09-13 Abbvie Inc IL-17 BINDING PROTEINS
ES2693194T3 (en) 2009-06-16 2018-12-10 Genzyme Corporation Improved methods for the purification of recombinant AAV vectors
EP2485763A4 (en) * 2009-10-10 2013-10-30 Univ Leland Stanford Junior Il-17 family cytokine compositions and uses
CA2825561A1 (en) * 2011-01-25 2012-08-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Methods of diagnosing and treating age-related macular degeneration
CN103796667A (en) * 2011-06-22 2014-05-14 艾普莱斯制药公司 Methods of treating chronic disorders with complement inhibitors
WO2014107737A2 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease

Also Published As

Publication number Publication date
US20210040484A1 (en) 2021-02-11
EP2986310A1 (en) 2016-02-24
AU2014253919B2 (en) 2019-06-20
CN115715797A (en) 2023-02-28
SG10201912901YA (en) 2020-02-27
CA2909706C (en) 2023-02-14
MX2015014568A (en) 2016-12-02
EP2986310B1 (en) 2020-08-05
US10640771B2 (en) 2020-05-05
CN105682674A (en) 2016-06-15
AU2014253919A1 (en) 2015-11-12
US20160068844A1 (en) 2016-03-10
WO2014172560A1 (en) 2014-10-23
SG11201508297YA (en) 2015-11-27
CA2909706A1 (en) 2014-10-23
EP3741385A1 (en) 2020-11-25
CA3182572A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
IL281058A (en) Compositions and methods for treating anemia
IL245778B (en) Methods and compositions for treating hemophilia
HK1221735A1 (en) Compositions and methods for treating mpsi mps1
IL246023B (en) Methods and compositions for treating aging-associated conditions
HK1218656A1 (en) Age-related macular degeneration treatment
IL245281A0 (en) Methods and compositions for treating cancer
HK1214521A1 (en) Compositions and methods for treating proteinopathies
ZA201505390B (en) Compositions and methods for treating pests
EP2953950A4 (en) Compositions and methods for treating neurodegenerative diseases
HK1217490A1 (en) Novel traps in the treatment of macular degeneration
SG11201508297YA (en) Compositions and methods for treating and preventing macular degeneration
IL247116B (en) Compositions and methods for treating and preventing macular degeneration
EP2968452A4 (en) Compositions and methods for treating retinal disease
IL243022B (en) Compositions and methods for post-harvest treatment
EP2971044A4 (en) Compositions and methods for treating cancer
GB201302475D0 (en) Compositions and methods for treating biofilms
GB201302472D0 (en) Compositions and methods for treating biofilms
GB201302474D0 (en) Compositions and methods for treating biofilms